WEZENLA 130 mg/26 ml conc perf 130 mg 1 pce

7680701870015 CH-70187 L04AC05 07.15.0.

Active substances:

Ustekinumabum

No images available

Details

Product number
7018701
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
ustekinumabum 130 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, dinatrii edetas, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 26 ml, natrium 0.097 mg.

Articles (1)

Wezenla 130 mg/26 ml, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
29/04/2026
Professional SmPC
Français
29/04/2026
Professional SmPC
Italien
29/04/2026

Detailed composition

Substance Quantity Type Category
ustekinumabum
130.0 MG Substance Wirkstoff (Principe actif)
saccharum
- Substance HNIDK
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
methioninum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
dinatrii edetas
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
0.097 MG Substance HBESI

Reimbursement information

Public price
CHF 1540.15
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/05/2026

Authorization holder

Amgen Switzerland AG

6343 Risch

Authorization information

Swissmedic authorization number
70187
Drug name
Wezenla, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
L04AC05
Authorization status
Z
Dispensation category
B
First authorization
23/07/2025
Authorization expiration date
22/07/2030
IT number
07.15.0.
Domain
Human medicine
Field of application
Morbus Crohn, Ulcerative Colitis

Packaging details

Description (FR)
WEZENLA 130 mg/26 ml conc perf 130 mg 1 pce
Description (DE)
WEZENLA 130 mg/26 ml Konz Inf 130 mg 1 Stk
Market launch
29/04/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data